Oct 29, 2019 Syros Presents New Preclinical Data on SY-5609, Its Highly Selective Oral CDK7 Inhibitor, at AACR-NCI-EORTC International Conference
Oct 24, 2019 Syros Announces New Data from Phase 2 Trial of SY-1425 in Combination with Azacitidine Demonstrating High Response Rates, Rapid Onset of Action and Favorable Tolerability Profile in RARA-Positive Newly Diagnosed Unfit AML Patients
Aug 1, 2019 Syros Reports Second Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
May 7, 2019 New Publication in Cancer Research Highlights Discovery of SY-1365, a First-in-Class Selective CDK7 Inhibitor, and its Promise as a Potentially Transformative Targeted Approach for Difficult-to-Treat Cancers
May 1, 2019 Syros Reports First Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
